Digipede Joins the BioIT Alliance

Share Article

The BioIT Alliance is a group of software, biotech and pharmaceutical organizations working together to help realize the potential of personalized medicine with the Microsoft platform.

Digipede Technologies (http://www.digipede.net), a leading provider of distributed computing solutions for the Microsoft Windows platform, announced today it is joining the BioIT Alliance, a cross-industry group working together to realize the possibilities of personalized medicine with the Microsoft platform. The BioIT Alliance will enable the pharmaceutical, biotechnology, equipment manufacturing, and software industries to develop best practices for sharing biomedical data, improving collaboration, and effectively managing life sciences knowledge.

"Digipede is pleased to join Microsoft and its industry partners in this critical effort to convert scientific breakthroughs into practical therapies. Simplified access to high-performance computing is a key component of the initiative to develop personalized therapies,” said John Powers, CEO of Digipede Technologies. “As genomic analysis becomes economically feasible at a personal level, we see opportunities to bring supercomputing performance to every hospital, every clinic, and every doctor's office. The BioIT Alliance can help accelerate these opportunities, bringing real benefits to millions of patients.”

Digipede Technologies, along with the other BioIT Alliance members, are joining forces to improve the speed of drug discovery, gene sequencing and other compute-intensive life-saving therapies to ultimately improve the lives of consumers and give healthcare providers the ability to offer personalized therapies to their patients. Digipede's flagship distributed computing product, the Digipede Network, is in use at leading biotech labs and universities in North America and Europe, where the foundations of personalized therapies are being developed today.

“The ability to ‘scale out’ processing is increasingly important for our customers who use computational techniques for life science discovery,” said Don Rule, platform strategy advisor at Microsoft Corp. “We are glad to have Digipede as a member of the BioIT Alliance for its expertise in using the Microsoft .NET development environment to enable rapid application development for these scenarios.”

In addition, the Alliance has begun to address proof-of-concept demonstrations at Scripps Research Institute, which are designed to improve the ability to capture and annotate data in the laboratory. As the project progresses, the Alliance will be sharing the code that is developed as well as information on the implementation to help its member companies build applications faster and allow independent software vendors (ISVs) to incorporate these innovations into their software.

The Digipede Network is an affordable distributed computing solution built entirely on Microsoft .NET that dramatically improves the speed and performance of demanding real-world business applications. It is radically easier to buy, install and use than other grid-computing solutions. Using the Digipede Network, developers can easily write .NET-based applications that will take advantage of thousands of computers, bringing the power of High Performance Computing to the Windows platform.

The Digipede Network is available in two editions: the Digipede Network Team Edition meets the needs of small departments and labs that may only have up to 20 computers, while the Digipede Network Professional Edition supports large departments and enterprises with hundreds or thousands of desktops, servers, and cluster nodes across a network. Both editions include the Digipede Workbench, which is designed to shorten the learning curve so that users can become productive immediately. Through a familiar Windows user interface, users can run distributed computing jobs with ease. Wizards assist users with learning and using the system quickly, and powerful designers provide access to greater system functionality. No complex scripting is required.

Availability and Pricing

The Digipede Network is available now directly from Digipede Technologies. The Digipede Network Team Edition starts at $995 for a system licensing one Digipede Server and five Digipede Agents. The Digipede Network Professional Edition starts at $4,000 for a similar configuration. Additional Agents work with either edition, and can be licensed for $199 each. Current customers of the Digipede Network Team Edition can upgrade to the Professional Edition at a discount. Both editions of the Digipede Network include the acclaimed Digipede Framework SDK at no additional charge, providing unprecedented flexibility for grid-enabling enterprise applications. For additional information about pricing and configuration options, visit Digipede’s online store at http://www.digipede.net, or contact Digipede at sales@digipede.net.

About the BioIT Alliance

Formed in 2006, the BioIT Alliance is a cross-industry group working together to improve biomedical information technology on the Microsoft Platform. Founding members include Affymetrix, Accelrys, Amylin Pharmaceuticals, Applied Biosystems, BioTeam, Digipede Technologies, Discovery Biosciences, Geospiza, Hewlett Packard, InterKnowlogy, Microsoft, Sun Microsystems, VizX Labs and other key companies in the pharmaceutical, biotech, hardware, and software industries. For additional information about the BioIT Alliance, please visit the BioIT Alliance web site at http://www.bioitalliance.org.

About Digipede Technologies

Digipede Technologies is the leading software provider of grid computing solutions for the Microsoft .NET platform. Digipede is led by a proven team of technology visionaries who have developed best-in-class Windows applications for more than 15 years. Digipede is a Microsoft Gold Certified Partner. Headquartered in Oakland, California, Digipede is expanding rapidly. For more information visit http://www.digipede.net.

Digipede™, "Many Legs Make Light Work"™, and the Digipede logo are trademarks of Digipede Technologies. All other trademarks are the property of their respective owners.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Miiko Mentz
Visit website